Destiny Pharma PLC Director/PDMR Shareholding (1101N)
27 Septiembre 2021 - 09:18AM
UK Regulatory
TIDMDEST
RNS Number : 1101N
Destiny Pharma PLC
27 September 2021
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director Dealing
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage
biotechnology company focused on the development of novel medicines
to prevent life threatening infections, announces that it was
notified on 27 September 2021 that on that same day, Nick Rodgers,
Chairman of the Company, purchased 2,100 Ordinary Shares at a price
of 119.7999p per Ordinary Share. Following the transaction his
total beneficial interest is 56,073 Ordinary Shares, representing
0.09% of the total issued share capital of the Company.
The above purchase of shares is pursuant to the award of a 2020
bonus to Mr. Rodgers, payable in Destiny Pharma shares (on a net of
tax basis). The bonus is payable in two equal tranches following
the announcement of the Company' 2020 annual results and 2021
interim results.
Details of the full notification received by the Company are set
out below:
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Nick Rodgers
------------------------------- ----------------------------------
2. Reason for the Notification
-------------------------------------------------------------------
a) Position/status Chairman
------------------------------- ----------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ----------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ----------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ----------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
Financial instrument, in Destiny Pharma Plc
type of instrument
Identification code DEST GB00BDHSP575
------------------------------- ----------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------- ----------------------------------
c) Price(s) and volume(s) 119.7999 pence per Ordinary Share
2,100 Ordinary Shares
------------------------------- ----------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ----------------------------------
e) Date of the transaction 27 September 2021
------------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
------------------------------- ----------------------------------
Enquiries:
+44 (0) 1273 704
Destiny Pharma plc 440
Neil Clark (Chief Executive Officer)
Shaun Claydon (Chief Financial Officer and
Company Secretary)
finnCap Limited - Nominated Adviser and Joint
Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson
(Corporate Finance)
Alice Lane (ECM)
WG Partners LLP - Joint Broker +44 (0) 20 3705 9330
Nigel Barnes / Claes Spång / Nigel Birks
Optimum Strategic Communications +44 (0) 203 174 1789
Mary Clark / Hollie Vile / Manel Mateus
MC Services AG
Anne Hennecke / Andreas Burckhardt +49-211-529252-0
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information, please visit
https://www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFLSADIDFIL
(END) Dow Jones Newswires
September 27, 2021 10:18 ET (14:18 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024